Blueprint Medicines Corp. shifted away from two early clinical therapies for EGFR-mutant non-small-cell lung cancer and dropped development and commercialization of lung and thyroid cancer drug Gavreto (pralsetinib) for areas outside of the U.S. and greater China, reducing its operating expenses, as it prepares for increasing Ayvakit sales and prioritizes development of other assets.